The pharma giant is still seeing sluggish sales, but can Merck earnings move forward? Find out here.
Only four of the 30 Dow Jones stocks delivered positive returns in January. Here's how they did it.
Merck, CytRx, and Mylan are 3 health care stocks worth watching this morning. Here’s why.
Merck has struggled with the patent cliff's hit on its sales lately, but can this top pharma stock bounce back with earnings on tap?
There aren't many winning stocks in the Dow so far in 2014, but they have a few lessons for investors looking for better returns in a tough year.
Who will win the high-stakes immuno-oncology race?
Friday's health-care winners and losers.
Does this analyst make a good case? Or is it just more noise from Wall Street?
Merck and United Technologies join Caterpillar as leading blue-chip gainers on a mixed day for the Dow Jones.
After Friday's drop of more than 300 points, the Dow hasn't been able to sustain much of a rebound despite strong upward share-price moves for Caterpillar and Merck. Find out why.